Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study of TQB2922 for Injection in Patients With Advanced Cancers

NCT06188624 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06188624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06188624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study of TQB2922 for Injection in Patients With Advanced Cancers
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
February 1, 2024
Completion date
December 31, 2027
Enrollment
150 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer